OncoTartis

About:

A private biotechnology company.

Top Investors: Millhouse, Pharmstandard International

Description:

OncoTartis, Inc. is a private biotechnology company established in 2011. Company’s founding IP came from Prof. Andrei Gudkov’s laboratory at Roswell Park Cancer Institute (Buffalo, NY). OncoTartis develops a novel category of anti-cancer drugs directed against tissue-specific targets for a subset of cancers (breast, prostate, ovarian, melanoma and hematological malignancies). Its leading product OT-82 is a nicotinamide phosphoribosyltransferase (NAMPT) inhibitor being developed to treat Acute Myeloid Leukemia (AML). Investigational New Drug application (IND) will be submitted to FDA in the forth quarter of 2017.

Total Funding Amount:

$6M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Buffalo, New York, United States

Founded Date:

2011-01-01

Contact Email:

info(AT)oncotartis.com

Founders:

Alexander Polinsky, Andrei Gudkov, Olga Chernova

Number of Employees:

1-10

Last Funding Date:

2017-12-11

IPO Status:

Private

Industries: